{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T04:58:59Z","timestamp":1781326739863,"version":"3.54.1"},"reference-count":17,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diagnostic Microbiology and Infectious Disease"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1016\/j.diagmicrobio.2020.115107","type":"journal-article","created":{"date-parts":[[2020,6,11]],"date-time":"2020-06-11T12:36:52Z","timestamp":1591879012000},"page":"115107","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Comparison of minimum inhibitory concentration results for gepotidacin obtained using agar dilution and broth microdilution methods"],"prefix":"10.1016","volume":"98","author":[{"given":"S.J. Ryan","family":"Arends","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele A.","family":"Canino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodrigo","family":"Mendes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole E.","family":"Scangarella-Oman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert K.","family":"Flamm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.diagmicrobio.2020.115107_bb0005","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1038\/nature09197","article-title":"Type IIA topoisomerase inhibition by a new class of antibacterial agents","volume":"466","author":"Bax","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.diagmicrobio.2020.115107_bb0010","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1128\/AAC.02820-15","article-title":"In vitro activity of gepotidacin, a novel triazaacenaphthylene bacterial topoisomerase inhibitor, against a broad spectrum of bacterial pathogens","volume":"60","author":"Biedenbach","year":"2016","journal-title":"Antimicrobial agents and chemotherapy"},{"key":"10.1016\/j.diagmicrobio.2020.115107_bb0015","series-title":"Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard- tenth edition","article-title":"M07-A10","author":"CLSI","year":"2015"},{"key":"10.1016\/j.diagmicrobio.2020.115107_bb0020","series-title":"Development of in vitro susceptibility testing criteria and quality control parameters: fourth edition","article-title":"M23-A4","author":"CLSI","year":"2016"},{"key":"10.1016\/j.diagmicrobio.2020.115107_bb0025","series-title":"Performance standards for antimicrobial susceptibility testing: 30th informational supplement","article-title":"M100Ed30","author":"CLSI","year":"2020"},{"key":"10.1016\/j.diagmicrobio.2020.115107_bb0030","doi-asserted-by":"crossref","first-page":"114867","DOI":"10.1016\/j.diagmicrobio.2019.07.005","volume":"95","author":"Emiliov","year":"2019","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2020.115107_bb0035","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02047-16","article-title":"In vitro activity of gepotidacin (GSK2140944) against Neisseria gonorrhoeae","volume":"61","author":"Farrell","year":"2017","journal-title":"Antimicrobial agents and chemotherapy"},{"key":"10.1016\/j.diagmicrobio.2020.115107_bb0040","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00468-17","article-title":"Gepotidacin (GSK2140944) In vitro activity against Gram-positive and Gram-negative bacteria","volume":"61","author":"Flamm","year":"2017","journal-title":"Antimicrobial agents and chemotherapy"},{"key":"10.1016\/j.diagmicrobio.2020.115107_bb0045","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1021\/acsinfecdis.8b00315","article-title":"Mechanistic and structural basis for the actions of the antibacterial gepotidacin against Staphylococcus aureus gyrase","volume":"5","author":"Gibson","year":"2019","journal-title":"ACS Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2020.115107_bb0050","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.mimet.2019.01.001","article-title":"Comparison of Neisseria gonorrhoeae minimum inhibitory concentrations obtained using agar dilution versus microbroth dilution methods","volume":"157","author":"Jacobson","year":"2019","journal-title":"J Microbiol Methods"},{"key":"10.1016\/j.diagmicrobio.2020.115107_bb0055","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1093\/jac\/dky162","article-title":"In vitro activity of the novel triazaacenaphthylene gepotidacin (GSK2140944) against MDR Neisseria gonorrhoeae","volume":"73","author":"Jacobsson","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.diagmicrobio.2020.115107_bb0060","doi-asserted-by":"crossref","first-page":"4404","DOI":"10.1128\/AAC.00527-16","article-title":"Multicenter investigation of gepotidacin (GSK2140944) agar dilution quality control determinations for Neisseria gonorrhoeae ATCC 49226","volume":"60","author":"Jones","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2020.115107_bb0065","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1128\/JCM.02366-16","article-title":"Analysis of MIC and disk diffusion testing variables for gepotidacin and comparator agents against select bacterial pathogens","volume":"55","author":"Koeth","year":"2017","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.diagmicrobio.2020.115107_bb0070","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02095-16","article-title":"Efficacy, safety, and tolerability of gepotidacin (GSK2140944) in the treatment of patients with suspected or confirmed gram-positive acute bacterial skin and skin structure infections","volume":"61","author":"O'Riordan","year":"2017","journal-title":"Antimicrobial agents and chemotherapy"},{"key":"10.1016\/j.diagmicrobio.2020.115107_bb0075","doi-asserted-by":"crossref","first-page":"4321","DOI":"10.1128\/JCM.43.9.4321-4327.2005","article-title":"Cultivation of Neisseria gonorrhoeae in liquid media and determination of its in vitro susceptibilities to quinolones","volume":"43","author":"Takei","year":"2005","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.diagmicrobio.2020.115107_bb0080","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1093\/cid\/ciy145","article-title":"Gepotidacin for the treatment of uncomplicated urogenital gonorrhea: A phase 2, randomized, dose-ranging, single-oral dose evaluation","volume":"67","author":"Taylor","year":"2018","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2020.115107_bb0085","series-title":"Guidance for industry and FDA; Class II special controls guidance document: Antimicrobial Susceptibility Test (AST) systems","author":"USA-FDA","year":"2009"}],"container-title":["Diagnostic Microbiology and Infectious Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0732889320304843?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0732889320304843?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T09:55:05Z","timestamp":1760003705000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0732889320304843"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":17,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["S0732889320304843"],"URL":"https:\/\/doi.org\/10.1016\/j.diagmicrobio.2020.115107","relation":{},"ISSN":["0732-8893"],"issn-type":[{"value":"0732-8893","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparison of minimum inhibitory concentration results for gepotidacin obtained using agar dilution and broth microdilution methods","name":"articletitle","label":"Article Title"},{"value":"Diagnostic Microbiology and Infectious Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diagmicrobio.2020.115107","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"115107"}}